Open an account

Teva Pharmaceutical Industries

TEVA · TEL

$40.85−$0.46 (−1.11%)TodayMarket closed ·
Prev close $41.31

About TEVA

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The company employs 31,173 full-time employees The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Employees
31,173
Headquarters
TEL AVIV-YAFO
Listed
Jan 1, 1951
Sector
Health Care
Industry
Pharmaceuticals
Website
tevapharm.com

TEVA key statistics

Market cap
150.67B
Price-earnings ratio
68.85
Dividend yield
—
Average volume
6.47M
Volume
4.22M
Open price
$41.48
High today
$41.59
Low today
$40.80
52 Week high
$42.02
52 Week low
$16.74

Teva Pharmaceutical Industries (TEVA) at a glance

As of Oct 20, 2026, Teva Pharmaceutical Industries (TEVA) shares are priced at $40.85, giving the company a market cap of 150.67B and a price-to-earnings ratio of 68.85.

Today the stock has traded between $40.80 and $41.59. The current price is 0.1% above the day's low and 1.8% below its high.

Volume so far is 4.22M shares, below the average of 6.47M shares a day.

Over the past year Teva Pharmaceutical Industries has ranged from $16.74 to $42.02, and now sits 95% of the way up that range.

Teva Pharmaceutical Industries met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.02 per share against an estimate of $0.2516.

The average analyst price target is $0.1347, 99.7% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $0.1347
Low
$0.1074
Now
$40.85
High
$0.1692

TEVA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 11.3% on average.

  1. Q3 FY24: reported $0.69 per share against an estimate of $0.6698
  2. Q4 FY24: reported $0.71 per share against an estimate of $0.696
  3. Q1 FY25: reported $0.52 per share against an estimate of $0.4913
  4. Q2 FY25: reported $0.66 per share against an estimate of $0.6307
  5. Q3 FY25: reported $0.78 per share against an estimate of $0.6695
  6. Q4 FY25: reported $0.96 per share against an estimate of $0.6929
  7. Q1 FY26: reported $0.53 per share against an estimate of $0.4872
  8. Q2 FY26: reported $0.02 per share against an estimate of $0.2516

TEVA news

  • Vandana Singh

    FDA Approves Teva's New Once-Monthly Schizophrenia Injection

  • Dylan Berman

    Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

  • Press releasePRNewswire

    Temporal Raises $550 Million in Series E Round: NYSE Content Update

  • Vandana Singh

    Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

  • Dylan Berman

    Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study

  • Namrata Sen

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

  • Akanksha Bakshi

    BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid

  • Vandana Singh

    Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Similar companies

Companies in the same industry as Teva Pharmaceutical Industries

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.